Multiple studies published in the last two years indicate that eggs from chickens immunized againstSARS-CoV-2could be used to create effective treatments againstCOVID-19in humans. There is no evidence, however, that this development is responsible for the current egg shortage in the United States, as some conspiracy theories allege.
In a study published in the Journal of Applied Microbiology March 2022, researchers found that egg antibodies (IgYs) produced by chickens immunized against the SARS-CoV-2 spike protein had the ability to neutralize the virus, specifically by interfering with the spike protein’s capacity to attach to human cells.
The researchers concluded that IgY targeting the spike protein “could be a promising candidate for pre- and post-exposure prophylaxis or treatment of COVID-19.”
They added that “administration of IgY-based oral preparation, oral or nasal spray may have profound implications for blocking SARS-CoV-2.”
A 2021 study published in the journal International Immunopharmacology concluded that anti-spike protein IgYs “showed significant neutralizing potency against SARS-CoV-2 pseudovirus, various spike protein mutants, and even SARS-CoV in vitro.”
The authors concluded such antibodies “might be a feasible tool for the prevention and control of ongoing COVID-19.”
This study also suggested that such a treatment might have several advantages over monoclonal antibodies, including reduced side effects and reduced production costs. As the authors point out, IgYs have been noted by researchers since 1959 for “their stable chemical properties” and low cost, high yield results that make them a potentially more attractive treatment option for developing countries.
When it comes to reduced side effects, the study notes, “IgYs neither bind the human rheumatoid factors, nor activate the human complement system, which minimizes the risks of inflammation.” In essence, egg antibodies do not cause allergy or set off immune reactions when injected into humans.
The study points out that IgY antibodies have also been applied to combat human viral infections such as the respiratory syncytial virus (RSV), influenza virus, and Coxsackie virus.
The authors cite a 2006 study of an earlier SARS coronavirus in which anti-SARS coronavirus IgYs were purified from chickens immunized with an inactive form of the virus, and the resulting antibodies were able to neutralize the live virus both in vitro and in vivo.
A third study published last in Viruses last July by researchers at UC-Davis also found evidence supporting the approach of producing COVID-19 antibodies in birds.
Rodrigo Gallardo, a UC-Davis professor in poultry medicine at the UC Davis School of Veterinary Medicine lauded the approach in an article on the university’s website.
“The beauty of the system is that you can produce a lot of antibodies in birds. In addition to a low cost to produce these antibodies in hens, they can be updated very fast by using updated antigens to hyperimmunize hens, allowing protection against current variant strains.”
The Egg Shortage Theory
The egg antibody research offers such a compelling avenue for COVID-19 treatment that it has spurred questions of a potential conspiracy given the current egg shortage in the United States.
An article in the DCPatriot asked, “Is that why eggs are disappearing at an alarming rate? Is that why chicken farms are being destroyed? We don’t know, but it sure is a ‘what the hell is happening here’ moment, isn’t it?”
However, even though chickens can be used to produce antibodies, they first have to be exposed to the virus. All the studies involved hens that were exposed to the coronavirus. The study published in Applied Microbiology found that a control group of non-immunized IgYs had “no obvious inhibitory effect on the virus” as indicated in the graph below that compares the results of IgYs from immunized hens (blue line) to those of the control group (red line):
Luminescence inhibition rate curve of the anti-(SARS-Cov-2) IgY (blue) and normal (control) IgY (red) from the pseudovirus neutralization assay. (Elsevier COVID-19 resource centre)
There appears to be no scientific evidence then that the eggs in your local supermarket are an effective treatment for COVID-19. Furthermore, the contemplated delivery systems, such as nasal sprays, would deliver a highly refined and concentrated dosage, further enhancing the impact of the antibodies.
Eggs as COVID-19 Fighters
That said, as reported by the Times of India, “coronavirus quarantine facilities around the world, are offering eggs to their patients in recovery with their daily meals.”
The Times reported that authorities are also providing a lot of healthcare workers eggs daily to boost their immunity.
Eggs come packed with amino acids and antioxidants, which improve your health and keep your immune system functioning optimally.
Each egg (85 calories) contains 7 grams of muscle-building protein apart from essential core vitamins like selenium (22 percent) and vitamin A, B and K. Eggs also contain another nutrient, riboflavin, which supports development and growth.
Each egg also provides 27 percent of the RDA of vitamin D, which a recent meta-analysis (2022) of multiple studies has shown to be effective in reducing instances of COVID-19 infection as well as the severity of infections.
Chinese study made coronavirus antibodies in eggs by vaccinating hens
A 2021 study in China investigated antibodies generated by immunizing hens with a specific protein from the SARS-CoV-2 virus and found that the antibodies extracted from yolks could neutralize some versions of the coronavirus tested in the lab.
The results do not mean that all egg yolks contain coronavirus-neutralizing antibodies or that eating eggs would prevent COVID-19, as suggested in some widely shared posts online.
“So EGGS prevent COVID. Do you see it yet?,” reads one Feb. 2 comment on Twitter attaching an extract of the paper that has garnered over 3,600 retweets (here). Other examples can be seen on Instagram (here) (here).
Posts refer to a study originally published in November 2020 (here), which analyzed immunoglobulin Y (or lgY) antibodies generated in the yolks of eggs from laying hens that had been immunized with the “spike” protein from SARS-CoV-2. The researchers then tested the antibodies in human cells in the lab and found that they could block versions of a mock SARS-CoV-2 virus, and even SARS-CoV-1, from binding to the ACE-2 receptor these viruses normally use to enter human cells.
Qinglin Meng, a senior author of the study, did not immediately respond to a Reuters request for comment.
Not all eggs, however, contain the specific antibodies that neutralize SARS-CoV-2, Rodrigo Gallardo, professor in poultry medicine at the UC Davis School of Veterinary Medicine, told Reuters via email.
“Even though all hens and egg yolks contain lgY’s, in order to obtain those that neutralize SARS-CoV-2 you need to immunize (vaccinate) hens with a vaccine containing the virus, proteins, subunits or mRNA from the virus,” he said.
Gallardo coauthored a similar study conducted in 2022 at UC Davis (here) , which found that the purified antibodies from eggs harvested from hens given high doses of the SARS-CoV-2 spike protein could “neutralize” the virus in-vitro (here )
Producing lgY antibodies in eggs by immunizing hens has long been used as a way to generate large quantities of antibody quickly for use in treating diseases in other animals, as described in a 2011 review of the field (here).
During the pandemic, many researchers have also focused on the potential for employing this relatively inexpensive method to produce lgY antibodies in eggs for use in treating or preventing COVID in humans (jogh.org/2022/jogh-12-05009), (here) .
Such treatments are not likely to be delivered by having people consume the eggs. Rather, the process would extract and purify the antibodies made in the eggs, then use them like other antibody medications, which are typically given intravenously (www.mdpi.com/1999-4923/10/3/83) , (www.mdpi.com/1999-4923/10/3/83) .
Some posts referring to the November 2020 Chinese study (whose final version was formally published in January 2021) conflate the false idea that eggs treat COVID with the rise of egg prices in the United States (here) and even with a large fire that broke out at an egg farm in Connecticut on Jan. 28 (here).
One Twitter user commented, “Yes, that may be why there’s a shortage… very fishi,” and another wrote, “That makes a lot of sense now why egg farms are going up in spoke...(sic).”
According to the U.S. Department of Agriculture, however, a worldwide outbreak of avian flu that has killed millions of commercial chickens is among the causes for the increase in egg prices (here)
Hillandale Farms, operator of the egg farm in Bozrah, Connecticut that is mentioned in some posts, has said the cause of the fire is still being investigated (here). The fire would not impact egg prices, a spokesperson for the Department of Agriculture told NBC Connecticut (here).
VERDICT
Misleading. A study in China immunized hens to generate antibodies against SARS-CoV-2 in their eggs, it did not find that all eggs contain such antibodies or that eggs have any effect on COVID.
The ten largest food and beverage companies in the world remain Nestle, Ahold Delhaize, PepsiCo., Archer Daniels Midland, Sysco, JBS, Performance Food Group, Anheuser-Busch InBev, Unilever, and Tyson Foods. The global food and beverage industry remains one of the largest and most resilient sectors of the world economy, generating trillions of dollars in annual revenue . While consumer preferences, inflation, GLP-1 drug demand shifts, and supply-chain realignments continue to reshape the market, a relatively small group of multinational corporations still dominate global food sales. This May 2026 update revises our rankings using confirmed full-year 2025 results from company filings, SEC disclosures, and official press releases. Several rankings have shifted materially — most notably JBS, which reported record 2025 revenue of $86.2 billion and moves up from #6 to #4. Methodology: Rankings based on the most recent full fiscal year (FY2025) revenue from public filings, emphasizing ...
Artificial intelligence (AI) is redefining what wearable technology can do. In 2026, wearables are no longer passive tracking devices — they are becoming intelligent, predictive, and deeply personalized health and lifestyle companions. Source: Grand View Research Wearable technology market size was $92.90 billion in 2025 and is projected to reach $229.97 billion by 2033, growing at a CAGR of 12.1% from 2026 to 2033. ( Grand View Research ) Recent advances in intelligent wearable systems: from multiscale biomechanical features towards human motion intent prediction (source: Nature 2026 ) A landmark study published in The Lancet (2026) , drawing on wearable data from more than 135,000 adults, found that even modest increases in daily movement — and small reductions in sedentary time — were associated with meaningfully lower mortality rates. Wearables are no longer just fitness tools; they are preventive medicine infrastructure. From smart rings and AI fitness coaches to augmen...
Wearable technology in 2026 is no longer just about counting steps or tracking calories. It has evolved into a continuous, AI-powered health intelligence system —capable of predicting disease, optimizing performance, and even augmenting human capabilities. A large study, published in The Lancet (2026) and drawing on wearable-device data from more than 135,000 adults, found that remarkably small increases in daily movement — and modest reductions in sitting — were associated with meaningful drops in mortality (death-rate). We are entering a new phase: Wearables → Health Intelligence Platforms Wearable technology market size was $92.90 billion in 2025 and is projected to reach $229.97 billion by 2033, growing at a CAGR of 12.1% from 2026 to 2033. ( Grand View Research ) This article breaks down the most important innovations in wearable technology in 2026, and what they mean for consumers, healthcare, and investors. 1. Continuous Health Monitoring (24/7 Biometrics) Moder...
Table of Contents: Largest Pharma Companies by Revenue (Global Ranking) Top 10 Pharmaceutical Companies by Market Cap in 2025 Top 10 Most Anticipated Drug Launches of 2025 Top 10 Drugs Losing US Exclusivity in 2025 The largest pharma companies in the world play a central role in global healthcare, developing blockbuster drugs for cancer, cardiovascular disease, immunology, vaccines, and metabolic disorders. In 2025, the biggest pharmaceutical companies by revenue continued to dominate through scale, research spending, and global distribution—despite growing pressure from patent expirations, biosimilars, and pricing reforms. Medical stocks are releasing earnings reports in droves. Eli Lilly and Co (LLY.US) targets $80 billion in 2026 revenue with standout performance; Novo-Nordisk A/S (NVO.US) beats Q4 expectations but lowers 2026 guidance due to pricing pressures. The largest pharma companies are defined not only by revenue, but by global scale, research investment, and thera...
Last Updated: May 2026 | Reviewed by the One DayAdvisor Editorial Team Artificial intelligence is fundamentally changing what wearable technology can do. In 2026, wearables are no longer passive step counters — they are intelligent, predictive health and lifestyle companions that can detect illness early, coach your workouts, translate languages in real time, and monitor your brain activity while you sleep. The wearable technology market was valued at $92.90 billion in 2025 and is projected to reach $229.97 billion by 2033 , growing at a CAGR of 12.1% ( Grand View Research ). That growth is being driven almost entirely by AI. This guide covers the 10 most important AI wearable innovations in 2026, with honest product picks, real-world tradeoffs, and the emerging trends shaping the next few years. Table of Contents AI-Driven Health Monitoring and Early Detection Generative AI Wellness Coaches Smart Rings as Powerful Health Platforms AI Smart Glasses and Augmented Reality Wearables ...
As of 2026, consumer wearables have evolved into powerful health intelligence tools—tracking everything from heart rate and sleep stages to recovery (HRV), blood oxygen (SpO2), stress, and even early illness signals. But here’s the reality: No wearable is a medical device. Even the best trackers provide trend-level insights—not diagnoses . This guide ranks the most accurate fitness trackers and wearables in 2026 , based on: Heart rate accuracy (especially during workouts) Step and distance tracking reliability Sleep tracking consistency Real-world battery life Depth of health and recovery insights We also factor in independent testing from sources like Wirecutter, Wareable, and CNET, plus real-world user feedback. Best Fitness Tracker Overall (2026): Garmin Venu 3 If you want one wearable that does almost everything well, this is it. Why it ranks #1: Among the most accurate wrist-based heart rate sensors Excellent GPS tracking (especially newer multi-band support) Industry-leading reco...
Exchange-traded funds (ETFs) remain one of the best ways to build long-term wealth in 2026. With a single purchase, investors can gain diversified exposure to hundreds — or even thousands — of stocks, bonds, commodities, or thematic sectors. The biggest investing themes shaping 2026 include: Artificial intelligence (AI) infrastructure Semiconductor and data-center expansion Higher-for-longer interest rates Dividend and cash-flow investing Global diversification beyond mega-cap U.S. tech Nuclear energy and electrification Related: Top ETF Picks for April 2026 (War-Adjusted Portfolio Strategy) For most investors, the ideal ETF portfolio combines: Low costs Broad diversification Long-term compound growth Exposure to powerful secular trends like AI and automation Here are the best ETFs to consider in 2026. How These ETFs Were Selected Each ETF was evaluated based on: Long-term performance and liquidity Expense ratio and fund structure Relevance to current macro conditions Useful...
Artificial intelligence is no longer a theme—it is becoming the core infrastructure of global economic growth . From semiconductor design to cloud computing, automation, defense systems, and drug discovery, AI is now embedded across every major industry. The global generative AI market size is calculated at USD 25.8 billion in 2024 and is predicted to reach around USD 11.08 billion by 2034, expanding at a CAGR of 45.6% from 2024 to 2034. ( statifacts ) With hyperscalers (Microsoft, Amazon, Google, Meta) projected to spend over $500 billion on AI capex in 2026 alone (up from prior estimates), demand for data centers, chips, networking, cooling, and power is exploding. This isn't just hype—it's a multi-year buildout rivaling the internet era, with supply shortages persisting into 2026. Update: Best ETFs to Buy During the 2026 Energy Crisis (Protect Your Portfolio Now) Our "One-Day Decision" guide focuses on act...
As we enter 2026, the memory and storage crunch predicted in late 2025 has materialized with even greater intensity. AI data centers continue to dominate global production of DRAM and NAND flash, pushing prices sharply higher and extending lead times across consumer, PC, and enterprise segments. Nearly every analyst firm and memory maker is now warning of looming NAND and DRAM shortages that will send SSD and memory prices skyrocketing over the coming months and years, with some even predicting a shortage that will last a decade. For the better part of two years, storage upgrades have been a rare bright spot for PC builders. SSD prices cratered to all-time lows in 2023 , with high-performance NVMe drives selling for little more than the cost of a modest mechanical hard disk. DRAM followed a similar trajectory, dropping to price points not seen in nearly a decade. In 2024, the pendulum swung firmly in the other direction, with prices for both NAND flash and DRAM sta...
Reviewed by: OneDayAdvisor Editorial Team Last Updated: April 2026 The global oncology market is entering a new phase in 2026—defined by immunotherapy dominance, CAR-T expansion, and next-gen targeted therapies . While legacy giants still dominate revenue, earnings reports from Q1 2026 show a clear shift toward innovation-driven growth and aggressive M&A activity . This updated ranking incorporates: Latest Q1 2026 earnings data Oncology revenue trends Pipeline strength and strategic positioning Competitive threats (patent cliffs, biosimilars) Related: Latest Breakthroughs in Cancer Treatment In This Article: Merck (MRK) Bristol Myers Squibb Johnson & Johnson AstraZeneca Roche Novartis Eli Lilly (LLY) AbbVie Astellas Celgene 1. Merck & Co. Merck (MRK: NYSE ticker for Merck & Co. ) reported strong Q4 2025 results on Feb 3, 2026, with revenue of $16.4 billion (5% increase ...
Comments